Investigating a protein that may help fight viruses like COVID-19 and other flaviviruses.
TMEM41B: a pan-flavivirus and pan-coronavirus host factor with antiviral potential
This study is looking at how two proteins, TMEM41B and VMP1, help viruses like coronaviruses and flaviviruses multiply, and by using special gene editing tools, researchers hope to find new ways to stop these viruses, which could lead to better treatments for people with viral infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rockefeller University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10884234 on NIH RePORTER |
What this research studies
This research focuses on understanding how the TMEM41B protein and its related protein VMP1 are involved in the lifecycle of viruses such as coronaviruses and flaviviruses. By using advanced CRISPR/Cas9 gene editing techniques, the researchers aim to disrupt these proteins in cells to see how it affects viral replication and infection processes. The goal is to uncover the mechanisms by which these viruses hijack host cell factors to replicate, which could lead to the development of new antiviral therapies. Patients may benefit from this research as it could lead to innovative treatments for viral infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals affected by viral infections, particularly those caused by coronaviruses or flaviviruses.
Not a fit: Patients with non-viral infections or those not affected by flavivirus or coronavirus infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antiviral drugs that target the mechanisms viruses use to infect cells, potentially improving treatment options for patients with viral infections.
How similar studies have performed: Other research has shown promise in targeting host factors for antiviral therapies, suggesting that this approach could be effective.
Where this research is happening
New York, United States
- Rockefeller University — New York, United States (Active)
Researchers
- Principal investigator: Rice, Charles M — Rockefeller University
- Study coordinator: Rice, Charles M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.